Calchan appoints Zahid Ali as chief scientific officer

UK biotech company Calchan has appointed Zahid Ali as chief scientific officer.

He brings extensive expeirence in the pain therapeutic area, with almost two decades of industry experience in international pharma companies. Dr Ali joins from Pfizer (NYSE: PFE) where he was a senior director of clinical research, responsible for early clinical development programs focused on pain research. Prior to this he held position of increasing seniority at GlaxoSmithKline (LSE: GSK), including director of discovery medicine.

Brenda Reynolds, chief executive of Calchan, said: “Zahid Ali’s appointment is an important one as we continue to assemble a strong team to develop our assets at Calchan.  I am delighted that Zahid has chosen to join us as his considerable experience and background, notably as a clinical director at Pfizer, will be invaluable.”